MATHEWS

Review Article

Mathews Journal of Case Reports

Nutrivigilance: Boon for the Safety and Efficacy of Nutraceuticals Formulations

Mohammad Nadeem Khan[1,*], Ashok Kumar[2], Praveen Chand Dubey[3], Mohammad Rafi[4]

[1]*Department of Pharmacology, Clinical Pharmacology, SAMC&PGI, Sri Aurobindo University, Indore, Madhya Pradesh, India*

[2]

[3]*Chairman SEAC, Government of Madhya Pradesh Bhopal Madhya Pradesh, India*

[4]*ADR Monitoring center (PvPi, Ghaziabad), Department of Pharmacology, SAMC&PGI, Indore, Madhya Pradesh, India*

ABSTRACT

Nutrivigilance is a corrective process originating in interactions between nutraceuticals formulations and human populations, investigating, in real situations of life, benefits, risks and use of nutraceuticals. Supplements include substances such as vitamins, minerals, botanicals, and amino acids. Although many of these supplements can be beneficial, there are risks correlated with some. For example, *ginkgo biloba* may lead to excessive bleeding, vitamin A in high dosages during pregnancy may lead to birth defects, and St. John's Wort may reduce the effectiveness of some antiviral formulations. Unlike new prescription and over-the-counter drugs or formulations, FDA does not have the authority to require supplements to undergo premarket approval for safety and efficacy. This is of major concern now a day to monitor the safety and adverse drug reactions (ADRs) related with the use of the Nutraceuticals". The USFDA, IPC and other country continuous ADR monitoring Nutraceuticals together became as a WHO Collaborating Centre. The Nutravigilance Programme of India encourages all healthcare professionals and consumers to report ADRs associated with nutraceuticals. We may be integrating the all stockholder to monitoring Programme of nutraceutical formulations adverse event monitor very precisely that are helpful to nutraceutical formulations compliance with more satisfied quality control and quality assurance and safe for consumer.

Keywords: Adverse drug reaction, Awareness, Nutraceutical formulations, Nutravigilance, Safety

INTRODUCTION

The term has chased "Nutrivigilance" by combining the terms" Nutrition and "Pharmaceutical" in 1989 by Dr. Stephen De Felice, Chairman of the Foundation for Innovation in Medicine. "Nutraceutical" is a marketing term developed for nutritive supplement that's used with the intent to treat or help conditions [1]. Nutraceutical refers to a food having medicinal effect on mortal health. It consists of food supplements, herbal products, probiotics and prebiotics meant for forestallment and treatment of conditions. Herbal products, insulated nutrients, salutary supplements and diets to genetically finagled ''developer'' foods and reused products similar as cereals, mists and potables may considered as nutraceuticals

Vol No: 08, Issue: 12

Received Date: December 01, 2023

Published Date: December 14, 2023

***Corresponding Author**

Mohammad Nadeem Khan

Department of Pharmacology, Clinical Pharmacology, SAMC&PGI, Sri Aurobindo University, Indore, Madhya Pradesh, India

Email: sahani.nadeem35@gmail.com

Citation: Khan MN, et al. (2023). Nutrivigilance: Boon for the Safety and Efficacy of Nutraceuticals Formulations. Mathews J Case Rep. 8(12):141.

[2]. Nutraceuticals has been expanded to include vitamins, minerals, amino acids, sauces and other botanicals and any salutary substances after the conformation of Dietary Supplement. Remedial benefits of nutraceuticals its use has increased worldwide beside the adverse goods associated with its use especially when consumed in large amounts. Lack of proper regulation of nutraceuticals in the pharmaceutical assiduity and easy vacuity of nutraceuticals and its regulation has surfaced the need to cover the adverse effect associated with use in public health [3]. Pharmacovigilance Programme of India encourages all healthcare professionals and consumers to report ADRs associated with Nutraceuticals. The submitted ADR reports are reviewed and anatomized at NCC and eventually submitted to World Health Organization-Uppsala Monitoring Centre (WHO- UMC), Sweden. The Nutravigilance is defined as "the wisdom and conditioning relating to the discovery, assessment, understanding, and forestallment of adverse goods related to the use of a food, salutary supplement, or medical food." [4]. In the United States, finished salutary supplement products and salutary constituents are regulated by the Food and Drug Administration (FDA) under the Dietary Supplement Health and Education Act of 1994. It also includes the reporting of adverse events to the FDA by all important stakeholders, including consumers, manufacturers, distributors, druggists, etc [5]. Herbal products or phytopharmaceuticals are included on the medicine's list with conditions of safety and quality norms and having the commitment to report adverse events in the European Union. Salutary supplements authorization doesn't bear any safety studies similar as preclinical, clinical, or toxicological studies compared to medicines. European regulations relate only to their manufacturing, processing, approving, trading, promoting, selling, and labeling. In India, food products are presently classified into nutraceuticals, health supplements, food for special salutary use, food for special medical purposes, prebiotics, probiotics, specialty foods, and new food, according to the Food Safety and Standards Authority of India (FSSAI). The FSSAI regulates food business licensing and enrollment, manufacturing, packaging, and labeling, food product standard, deals restrictions, poison, and pollutants slice, and laboratory analysis [6]. To maintain the quality and safety enterprises of nutraceuticals, it's a prerequisite for all companies to follow the nonsupervisory guidance of FSSAI. Still, there are no enterprises taken by FSSAI to proactively cover or record the adverse events arising due to the consumption of food products.

Nutrivigilance in Nutraceutical

Nutrivigilance is defined as 'the discovery, assessment, understanding, and forestallment of adverse goods of Nutraceutical or any other possible functional food, and salutary affiliated problems '. This description plainly covers the objects of the Pharmacovigilance in Modern medicine and their supplements and AYUSH program and its content area as per the WHO guidelines [7]. Although a specialized term fellow to "Nutravigilance" doesn't feature in any remedial expression textbooks, the spirit of Nutravigilance is vibrant throughout Ayurveda's classical literature. The Brihattrayi and Laghutrayi constantly emphasize the major pretensions of pharmacovigilance, to ameliorate patient care and safety during treatment, and therefore to promote rational use of specifics. These are intermittent themes of Ayurvedic pharmacology (Dravyaguna), pharmaceutics (Rasa Shastra and Bhaishjya Kalpana), and rectifiers (Chikitsa). It's probable that these introductory principles of Ayurveda gave rise to the common belief that Ayurvedic drugs are safe. The Ayurvedic literature gives details of medicine-medicine and medicine- diet incompatibilities grounded on elaborately described qualitative differences in constituents or quantitative proportions. These factors really help the onset of numerous else unfortunate responses [8]. Ayurveda's Anupan remedial system and Shodhan pharmaceutics principles presumably also contribute to the forestallment of numerous uninvited and unlooked-for events. Prevention of this kind is a major thing of Nutravigilance programs.

Pharmacovigilance Program Timeline

Conventional drug According to Composition-2 of the World Health Organization's constitution, its accreditation from its Member States is "to develop, establish, and promote transnational norms with respect to food, natural, pharmaceutical and analogous products." also, Article 21 authorizations that it borrow regulations concerning "norms with respect to the safety, chastity and energy of natural, pharmaceutical and analogous products moving in transnational commerce." In agreement with these judgments, WHO has acted veritably snappily whenever wide health diseases have arisen? The 1961 Thalidomide disaster was the driving stroke which impelled WHO to initiate a program to completely cover all specified medicines. In its sixteenth World Health Assembly in 1963, resolution WHA1636 emphasized the need for rapid-fire dispersion of information on ADRs. In 1968 as a result of reports of medicines producing adverse responses, WHO initiated, it's Pilot Research Project for International Drug Monitoring. The program fulfilled introductory purposes eventually, in 1997, WHO drew up the Erice Declaration, and transnational agreement ultimately inked by all member states to agree on invariant norms for reporting ADR's [9].

The Eric Declaration

The Eric Declaration represented significant progress. It challenges all players, including

- Public Health directors
- Health professionals
- The Pharmaceutical assiduity
- Governments
- Medicine controllers
- Media
- Consumers

To strive towards, the loftiest ethical, professional, and scientific norms in guarding and promoting the safe use of medicine and their phrasings. The protestation charges governments and all involved in determining programs relating to the benefit, detriment, effectiveness, and threat of drugs, to be responsible for what they communicate to both the public and cases. It calls for honesty when communicating medicine safety information, indeed when similar in formation is deficient and examinations are still underway [10]. It further stipulates that cases be transparently informed of all data, hypotheticals, and misgivings concerning safety biographies of their drugs. Considerable trouble has latterly been made to achieve its pretensions [7] farther in 2002, India agreed to shoot all its ADRs arising from use of conventional drug to WHO's ADR Monitoring Centre in Uppsala, Sweden, where its transnational ADR database receives reports from National Centers in 65 countries using ' Med-DRA ' and WHO- ART language the ' Medical Dictionary for Drug Regulatory Conditioning ' and ' World Health Organization Adverse response language 'for ADR's [11] India introduced the program in agreement with scores from agreements inked in 1997 and 2002. A new public network of Pharmacovigilance centers was established in 2004, coordinated by the Central medicines Standard Control Organization (CDSCO). Preliminarily, from 1980, the program was coordinated by ICMR (Indian Council of Medical Research) through its adverse medicine reporting centers, up to 1986, when a formal ADR monitoring system was introduced. This comported of 12 regionalcenters, each responsible for a population of 50million [12]. In this program, it's mandatory to report any ADR from a croaker, and as an essential element of medicine safety, pharmaceutical companies must also submit periodic safety update reports grounded on post marketing surveillance [13]. A common understanding between all the Pharmacovigilance program's conventional drug stakeholders in India was that, to deal with certain objects not addressed by the 2004 system, the program should be reorganized. The program was re-launched in April 2010 by CDSCO in association with a new crucial player, the Department of Pharmacology of the All India Institute of Medical Sciences (AIMS), New Delhi. Up to now, further than 40 medical sodalities have been nominated as Pharmacovigilance centers under a policy aiming to cover all medical sodalities in the country. For conventional drug, the program has therefore been redesigned, and enforced in the stopgap that it'll give a fool- evidence system of icing drugs ' safety [12,13].

Relevance of Nutrivigilance to the Current Practice in India

Food products may lead to several adverse events, which are determined by Ôhe inherent adverse effects of dietary supplements prompted by the active substances Drugs and dietary supplements interactions Adverse events related to adulteration to improve the activity with Active pharmacologically substances (API) such as steroids and neuro-stimulators [14]. The examples include Vitamin D3 and calcium phosphate, leading to constipating bloating, metallic taste, thirst, tiredness, weakness, loss of appetite, and muscle pain and also when given along with quinolones, tetracycline lead to decreased antibiotic absorption [15]. Green tea extract (Camellia sinensis) is used to reduce body weight and is associated with liver injury when combined with warfarin.[16] Aloe-vera (Aloe barbadensis miller), which is commonly used in India associated with adverse effects such as gastrointestinal complaints, arrhythmias, nephropathies, and edema, and when given along with anti-diabetics, causes hypoglycemia [17].

Nutrivigilance – Indian Scenario

The conception of Nutrivigilance is fairly new in India, unlike that of Pharmacovigilance for reporting adverse events due to medicines. The devoted Pharmacovigilance program of India was launched, which commanded adverse medicine response monitoring [18]. Presently, no specific Indian guidelines live for Neutraceutic's or salutary surveillance, including post-market surveillance programs for Neutraceutics. Tools and guidelines for signal discovery need to be developed [19]. A proper reason assessment structure or algorithm for nutraceutical supplements that considers the natural complexity of the product classes and subcategories is demanded. A methodical and formalized frame will be helpful for both the FSSAI and the food assiduity in deciding whether a particular product or component poses overdue health pitfalls with poor threat – benefit rate that requires acceptable threat relief strategies. A current demand is to ameliorate the domestic adverse event reporting process due to the recent swell in salutary supplements. Analysis of reported adverse events and conduct taken concerning reported adverse

events should be made public [20]. In view of the adding frequentness of adverse medicine responses (ADRs) due to illogical operation of nutraceuticals, the Pharmacovigilance Programme of India (PvPI) has prompted the stakeholders to use channels of reporting ADRs developed by Indian Pharmacopoeia Commission (IPC). Indian Council of Medical Research- National Institute of Nutrition (ICMR- NIN), Hyderabad is one of the PvPI uniting centers for covering the safety of nutraceuticals. Presently, PvPI receives a veritably limited number of ADRs related to the use of nutraceuticals, health and food supplements. Thus, it has been prompted to all stakeholders including clinicians, nurses, druggists, other confederated health workers and public to report all adverse events associated with nutraceuticals, health and food supplements. PvPI has prompted to use channels of reporting similar events like PvPI Forms (Suspected ADR Reporting Form/ Medicines Side- goods Reporting Form), Dispatch address-(icsr.nccpvpi@gmail.com),(pvpi.compat@gmail.com), PvPI Helpline (1800-180-3024) and Mobile App(ADR PvPI). Ghaziabad grounded IPC is performing asa National Coordination Centre (NCC) for Pharmacovigilance Programme of India (PvPI) launched in 2010. Last time, the Union health ministry came out with suspected ADR form for healthcare professionals for reporting adverse medicine responses (ADRs) towards concentrated Pharmacovigilance (PV) [21]. It also came out with drugs side- effect reporting form for approved medicines in the country besides a risk free helpline number in the interest of patient safety. Union health ministry has also assigned 270 ADR Monitoring Centers (AMCs) being in the country to establish clinical substantiation between the medicine and the adverse medicine response through a robust system of reason assessment. Central medicines Standard Control Organization (CDSCO) in collaboration with IPC had in the history also started auditing healthcare institutions through assessment on aspects like bribes and reason assessment in order to review the functioning of AMCs in the country [22]. The exercise was meant to induce mindfulness in medical institutions to put in place effective surveillance system for discovery of ADRs. All stakeholders' views on whether adverse goods due to nutraceuticals should be treated on par with that of medicines and what should be the specialized title for the sake of enforcing it with clarity. In a correspondence addressed to the stakeholders on safe use of nutraceuticals, PvPI stated, "As you all are apprehensive that the use of nutraceuticals, health supplements and foods for special salutary purposes is now wide among the civic as well as pastoral crowd in India. Prevalence of ADRs due to use of nutraceuticals in the history have thus raised enterprises for regularly covering safety of these products. " part of Clinical Pharmacist in Nutrivigilance piecemeal from reporting adverse events clinical pharmacist's part may include guidance on the explanation use of nutraceuticals and food- medicine relations. Clinical pharmacists can also help to make up scientific substantiation, evidence of conception, and conduct conditioning which include conceptualization, inauguration and perpetration of post marketing surveillance, real- world studies to accumulate substantiation on the safety and circulate the same to health-care professionals. Compass of Nutrivigilance in Nutraceuticals the pretensions of Neutracutical's Nutrivigilance program are to ameliorate

- Case care and safety when using nutraceutical phrasings and related interventions;
- Public health and safety records of nutraceutical phrasings
- Assessment of benefit, detriment, effectiveness, and threat of phrasings,
- Stimulant of safe, rational, and more effective (including cost effective) use, and creation of Understanding, education, and clinical training in Nutrivigilance for nutraceutical phrasings and its effective communication to the public. Numerous cases have been reported in the recent history regarding ADRs and medicine- medicine relations at colorful public and transnational forums [23].

DISCUSSION

That Nutraceutical phrasings are safe due to their natural origin is an universal conception, but it's true to the extent that numerous are used as food stuffsand earn the bracket Generally honored as Safe- GRAS. References in the Ayurvedic classics to possible adverse responses to certain Ayurvedic drugs or Nutraceutical phrasings warn us against accepting this generalities universal, still. This is particularly true if drugs aren't prepared duly, or if preconditions for their administration aren't admired by both croaker and case, which will increase the possibility of an ADR being. Charak Sutra Sthana 26 warns that substances contrary to deha-dhatus will be negative (virodha) towards them. Similar enmity may affect from parcels, combination, processing, place, time, cure etc. or nutraceutical expression. In Ayurveda, diet (ahar) is as important for cure as drug. The textbooks state that an disease can only be cured by following proper diet (pathya). In this environment, Charaka lists salutary incompatibilities between particular foodstuffs [24]

- Fish and milk
- Honey and ghee in equal volume
- Hot water after taking bhallataka
- Kampillaka cooked with adulation milk.

Negative food may be get ADRs Neutraceutic's overall approach is holistic in that it aims to return a case's physiology to its natural state of balance capability to return the physiology to its natural, holistic state. Indecorous cure schedules either in volume or duration may lead to ADRs. Also, for any herbal or herbo- mineral phrasings used in overdose or for inordinate time ages. The Nutrivigilance program promises to close the gap between 'Nutraceutical phrasings' implicit and reality. Some Ayurvedic citations use flowery language to describe certain phrasings' remedial value, for illustration, the effect of Grahani Kapat Rasa on dysentery/ diarrhea; also for certain vajikarna phrasings. There may be a huge gap between claimed and reality, suggesting assessment of their genuine value under Nutrivigilance. An important aspect of the Nutrivigilance is phrasings' profitable evaluation, which may be carried out at any stage in a health care strategy's life cycle. Data from similar studies differs from that for clinical trials, and requires business- style analysis. Similar profitable evaluation studies must be considered an integral element of a decision analysis system using multiple criteria and methodologies from different disciplines that help the program achieve its multifaceted targets. When new medicines are developed, the pharmacovigilance program with its social perspective requires profitable evaluation of all aspects of their use in treatment, including side goods, adverse responses, and their fresh treatment costs, in addition to routine remedial evaluation. The pharmaceutical assiduity also needs to take responsibility for these added angles of Nutrivigilance. The program may also be applied in cases where drugs are unapproachable, unaffordable, unsafe, or inaptly used; or where conflict of interest with manufacturers occurs, inadequately covered clinical trials, when patient reclamation is unethical or informed concurrence is shy. According to the December, 2008 announcement of Rule 170 of the medicines and Cosmetics Rule, 1945, numerous clinical trials are planned in future [25]. Successful perpetration of the Nutrivigilance or pharmacovigilance program nutrivigilance program requires pharmaceutical companies to demonstrate to both controllers and consumers that they're doing everything possible to compliance nutraceutical phrasings safety, including developing further effective ways to manage expression safety data. Effective analysis of data from adverse event reporting systems, and internal and external data sources are demanded to respond to controllers' safety inquiries or other issues. The program was reviewed on 21 January 2009 by the National Pharmaco-alert Consultative Committee for ASU medicines (NPCC- ASU). The evaluation meeting effectively rubbers tamped the program.

Among the issues of these meetings were several suggestions of measures to ameliorate the program's effectiveness. NPRC, Jamnagar, presented details of 103 ADRs reported from each over the country and their reason assessment [26]. This is a matter of some concern. More recent developments include constitution of Nutrivigilance centers at all stockholders.

CONCLUSION

On the base of the below, we conclude that there's a need for a proper post-marketing surveillance program to cover quality, safety, and efficacy of Nutraceutical supplements, which is now available in the form of National Pharmacovigilance Programme for AYUSH and allopathic medicine phrasings. The success of any Nutrivigilance system lies in its strength to help farther adverse responses on the base of information entered. This will be possible only when consumer and croakers are watchful and vitally alert to the onset or neutralize of any ADRs. They need to prioritize their benefactions to make the Nutrivigilance program for functional food or nutraceutical phrasings Indian regulations regarding food products, salutary supplements, and nutraceuticals are evolving. Still, there's a need for more strict regulations for Nutrivigilance, i.e., detecting, covering, and maintaining the database of adverse events associated with salutary supplements, including the reason assessment. Important stakeholders should come together and borrow a visionary, regular, structured, scientific, and formalized approach to the explanation safety of food products, and nutraceuticals like the one employed successfully in the nutraceutical assiduity.

REFERENCES

1. Morgovan C, Ghibu S, Juncan AM, Rus LL, Butucă A, Vonica L, et al. (2019). Nutrivigilance: A new activity in the field of dietary supplements. Farmacia. 67:537–544.

2. Center for Food Safety and Applied Nutrition (no date) Dietary Supplements, U.S. Food and Drug Administration. FDA. https://www.fda.gov/food/dietary-supplements.

3. Halat KM, Dennehy CE. (2003). Botanicals and dietary supplements in diabetic peripheral neuropathy. J Am Board Fam Pract. 16:47–57.

4. Kalaiselvan V, Srivastava S, Singh A, Gupta SK. (2019). Pharmacovigilance in India: Present scenario and future challenges. Drug Saf. 42:339–446.

5. Sanaei M, Banasiri M, Shafiee G, Rostami M, Alizad S, Ebrahimi M, et al. (2015). Calcium vitamin D3 supplementation in clinical practice: Side effect and satisfaction. J Diabetes Metab Disord. 15:5.

6. Schmitz SM, Lopez HL, MacKay D. (2014). Nutravigilance: Principles and practices to enhance adverse event reporting in the dietary supplement and natural products industry. Int J Food Sci Nutr. 65:129–134.

7. Resu NR, Manju MS, Kondaveti S, Kumar SB. (2019). Neutraceuticals and nutrivigilance – Present scenario in India. Int J Food Biosci. 2:35–40.
8. http://www.cdsco.nic.in/html/pharmaco.html
9. Sten O. (2008). Pharmacovigilance training with focus on India,Indian J Pharmacol. 40:S28-S30
10. Kulkarni RD. (1986). Reporting system for rare side effects of nonnarcotic analgesics in India: Problems and Opportunities. Med Toxicl. 1:110-113.
11. Arora D. (2008). Pharmacovigilance obligations of the pharmaceuticalscompanies, Indian J Pharmacol. 40:S13-S16.
12. http/www.cdsco.nic.in/home page /Pharmacovigilance protocol/list of all centre/
13. http/www.phamexcil.org/pharma in media
14. Anonymous. (2002). WHO Traditional Medicine Strategy 2002-2005. Geneva: WHO.
15. Thatte U. (2006). Proceedings of Pre conference workshop"Pharamacovigilance of Ayurvedic Medicines"
16. Chaudhary AK. (2007). (Organising Secretary), Technical Report, WHO sponsored Seminar cum Workshop on Safety Profile of Ayurvedic Dosage Forms.
17. Galib M, Acharya R. (2008). National Pharmacovigilance Programme for Ayurveda, Siddha and Unani Drugs, AYU. 4:191-193.
18. Anonymus. (2008). National Pharmacovigilance Protocol for ASUDrugs, IPGTRA. Gujarat Ayurveda Unversity.
19. http://www.whoindia.org/LinkFiles/TraditionalMedicine National Pharmacovigilance Protocol for AyurvedaSiddha Unani Drugs.pdf
20. http://ayurveduniversity.com/pharmococell.php
21. Dalvi SS, Nayak VK, Pohujani SM, Desai NK, Kshirsagar NA, Gupta KC. (1994). Effect of gugulipid on bioavailability of diltiazemand propranolol. J Assoc Physicians India. 42:454-455.
22. Shastri K, Chaturvedi GN. Samhita C, Sthana S. (2002). Vidyotini Hindi Commentary. Varanasi;: ChaukhambaBharati Academy. 26: 82-84.
23. http://www.indianmedicine.nic.in/notifications.asp
24. Pipasha B. (2007). Setting Standards for proactive Pharmacovigilancein India: The way Forward. Indian J Pharmacol. 39:124-128.
25. Keservani RK, Anil K, Ahmad SF, Baige ME. (2014). Nutraceutical and Functional Food Regulations in India. Jo Pharm Practice Community Med. 327-342
26. Rajanandh MG, Chamundeeswari D. (2017). Need of Pharmacovigilance in Ayush Drugs. J Pharmacovigilance. 5(1):1-2.